Evidence map›Paper›PMID 40833988›Full record

ArticlePLoS pathogens2025

Persistent type I interferon signaling within the brain of people with HIV on ART with cognitive impairment.

Yuyang Tang, Ling Xie, Ciniso Sylvester Shabangu, Dajiang Li, Gabriela da Silva Prates, Ashokkumar Manickam, Lilly M Wong, Antoine Chaillon, Edward P Browne, Sara Gianella and 5 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuyang TangDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Ling XieDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Ciniso Sylvester ShabanguDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Dajiang LiDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Gabriela da Silva PratesDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Ashokkumar ManickamDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Lilly M WongDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Antoine ChaillonDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.
Edward P BrowneDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Sara GianellaDepartment of Medicine, University of California, San Diego, La Jolla, California, United States of America.
Wenzhe HoDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States of America.
David M MargolisDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Xian ChenDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Wenhui HuDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States of America.
Guochun JiangDepartment of Medicine and UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0003-1911-5089

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Bruce Edward Torbett · 2022 to 2026
$36.7M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
California NeuroAIDS Tissue NetworkU24MH100928 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACHIM, CRISTIAN L, MOORE, DAVID J · 2013 to 2023
$13.9M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
DATA COORDINATING CENTER TO PROVIDE SERVICES TO WORK COLLABORATIVELY WITH THE NATIONAL NEUROHIV TISSUE CONSORTIUM CLINICAL SITES TO PROVIDE MANAGEMENT AND DATABASE CAPABILITIES, SCIENTIFIC EXPERTISE, 75N95023C00013 · NIDA · THE EMMES COMPANY, LLC · PI SHERMAN, SETH · 2023 to 2025
$11.2M
Project-004P01AI169609 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 2022 to 2026
$10.6M
NNTC Data Coordinating CenterU24MH100925 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S, SHERMAN, SETH · 2013 to 2022
$9.5M
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE75N95023C00015 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HADIJAH, VACTOR · 2023 to 2025
$9.0M
NIAID NIH HHS P01 AI169609NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI181655NIAID NIH HHS R01 AI186609NIAID NIH HHS R21 AI167709NIAID NIH HHS U54 AI170855NIAID NIH HHS UM1 AI164567NIDA NIH HHS 75N95023C00013NIDA NIH HHS 75N95023C00014NIDA NIH HHS 75N95023C00015NIDA NIH HHS 75N95023C00016NIDA NIH HHS 75N95023C00017NIDA NIH HHS 75N95024C00027NIDA NIH HHS DP2 DA051915NIDA NIH HHS R01 DA051893NIDA NIH HHS R01 DA055491NIMH NIH HHS R01 MH136852NIMH NIH HHS R21 MH128034NIMH NIH HHS U24 MH100925NIMH NIH HHS U24 MH100928NIMH NIH HHS U24 MH100929NIMH NIH HHS U24 MH100930NIMH NIH HHS U24 MH100931
6 · The paper itself

Abstract

To better understand the molecular mechanism that drives neuroinflammation, we analyzed the protein profiles of 27 brains from HIV with HIV (PWH) on antiretroviral therapy (ART), including various stages of HIV-associated neurocognitive disorders (HAND), and compared them to 9 HAND-negative controls. We found that most of the proteins that were increased-about 66.7%-were involved in immune response pathways. Of these, 23.3% were specifically related to type I interferon (IFN-I) signaling, which remains active in the brain through both HIV-related and unrelated mechanisms. Using single-cell RNA sequencing (scRNA-seq) on brain tissues collected during rapid autopsies from participants in the Last Gift cohort, we found that IFN-I signaling was especially strong in astrocytes, microglia (MG), and endothelial cells. In a mini-brain organoid model of acute HIV infection, IFN-I signaling was also highly active in astrocytes but less so in MG. Interestingly, IFN-I activation can happen without HIV being present-expression of human endogenous retrovirus-W1 (HERV-W1) Env can directly trigger this response in astrocytes, and it continues in glial cells even with effective ART. Together, our findings point to persistent IFN-I activation in glial and endothelial cells in the brain, which may contribute to neuroinflammation and cognitive disorders in PWH on ART.

Indexed as

BrainCognitive DysfunctionHIV InfectionsInterferon Type ISignal TransductionAdultAstrocytesFemaleHumansMaleMicrogliaMiddle AgedInterferon Type I

Identifiers

PMID40833988
PMCPMC12367146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.